Akademska digitalna zbirka SLovenije - logo
National and University Library, Ljubljana (NUK)
Naročanje gradiva za izposojo na dom
Naročanje gradiva za izposojo v čitalnice
Naročanje kopij člankov
Urnik dostave gradiva z oznako DS v signaturi
  • Učinkovitost in varnost Vasilipa pri bolnikih s hiperholesterolemijo = The efficacy and safety of Vasilip in patients with hypercholesterolemia
    Barbič-Žagar, Breda
    Vasilip (simvastatin) belongs to the group of HMG CoA reductase inhibitors, the primary effect of which is lowering of the total cholesterol and LDL cholesterol blood levels. In addition to this ... primary effect, simvastatin lowers the triglyceride and increases the HDL cholesterol blood levels. It prevents disease-related complications and reduces mortality in patients with ischemic heart disease. Contributing to this action is its slowing effect on the process of atherosclerosis. Namely, in addition to their effects on the blood lipid levels, HMG CoA reductase inhibitors were shown to possess other, non-lipid (pleiotropic) effects that may contribute to the stabilisation of the atherosclerotic plaque, improve endothelial function, influence the process of platelet aggregation and reduce inflammation. Krka launched Vasilip(simvastatin tablets) in Slovenia in the summer of 1999. At present, Vasilip is successfully marketed in all Krka's traditional markets (Poland, the Czech Republic, Slovakia, Russia, Croatia, the Baltic republics, Ukraine, Romania and Macedonia). In addition to a bioequivalence study which furnished evidence that the bioavailability of Vasilip produced by Krka is completely comparable to that of the original simvastatin, a few comparable and open clinical trials (in 470 patients) have already been concluded. Postmarketing studies including more than 700 patients are currently under way. Treatment with Vasilip (in daily doses of 10-20 mg administered to patients included in primary prevention, and in daily doses of 20-40 mg administered to patients included in secondary prevention) resulted in favourable, statistically significant changes in the serum levels of atherogenic and protective lipoproteins. (Abstract truncated at 2000 characters).
    Source: Krka v medicini in farmaciji. - ISSN 0351-6040 (23, [št.] 33, 2002, str. 33-49)
    Type of material - article, component part
    Publish date - 2002
    Language - slovenian
    COBISS.SI-ID - 17815257

source: Krka v medicini in farmaciji. - ISSN 0351-6040 (23, [št.] 33, 2002, str. 33-49)

loading ...
loading ...
loading ...

Shelf entry